000			02126 a2200565 4500
005			20250516100542.0
264		0	_c20121025
008			201210s 0 0 eng d
022			_a1528-0020
024	7		_a10.1182/blood-2012-04-423079 _2doi
040			_aNLM _beng _cNLM
100	1		_aStopeck, Alison T
245	0	0	_aA phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. _h[electronic resource]
260			_bBlood _cAug 2012
300			_a1210-7 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBevacizumab
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xdiagnosis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aRituximab
650	0	4	_aStandard of Care
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
650	0	4	_aVincristine _xadministration & dosage
650	0	4	_aYoung Adult
700	1		_aUnger, Joseph M
700	1		_aRimsza, Lisa M
700	1		_aLeBlanc, Michael
700	1		_aFarnsworth, Brent
700	1		_aIannone, Maria
700	1		_aGlenn, Martha J
700	1		_aFisher, Richard I
700	1		_aMiller, Thomas P
773	0		_tBlood _gvol. 120 _gno. 6 _gp. 1210-7
856	4	0	_uhttps://doi.org/10.1182/blood-2012-04-423079 _zAvailable from publisher's website
999			_c21895187 _d21895187